HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $16 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $16 price target.
Follow the latest Alpha Tau Medical Ltd. (DRTS) news and market headlines alongside the live DRTS price. Stay informed on what's moving DRTS.
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $16 price target.
Alpha Tau Medical reports a 100% objective response rate and strong safety in interim U.S. REGAIN glioblastoma trial data.
Gainers Akanda (NASDAQ:AKAN) shares increased by 55.1% to $2.11 during Monday's pre-market session. The market value of their outstanding shares is at $3.5 million. Alpha Tau Medical (NASDAQ:DRTS) stock rose
Take-Two rose 4% ahead of GTA VI’s Nov. 19 release on strong presales. GreenPower led gainers, while Datavault AI plunged 43%.
- All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival has not been reached, with a median follow-up of 6.9 months from trial enrollment (range 3.1 to 11.6
Alpha Tau Medical reported positive interim results from its REGAIN trial testing Alpha DaRT for recurrent glioblastoma treatment. All eight treated patients remain alive with a median follow-up of 6.9 months, 100% objective response rate in six evaluable patients (83.3% complete responses), 100% treatment feasibility, and no unanticipated serious adverse events. The company plans to continue enrollment toward 20 patients.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to DRTS, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.